SEC Filings
RTW Funds Hold 5.6% Of Larimar As The Drugmaker Seeks Accelerated Approval
Larimar's projected cash runway extends into late second quarter 2027, before its anticipated mid-2027 U.S. approval.
Larimar Therapeutics (LRMR) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
SEC Filings
Larimar's projected cash runway extends into late second quarter 2027, before its anticipated mid-2027 U.S. approval.
Earnings
Manufacturing spending fell as Larimar increased commercial preparations for nomlabofusp, its experimental Friedreich’s ataxia treatment.
Earnings
The company projects cash into late second quarter 2027 and targets a U.S. launch in the third quarter, if approved.